| 1 |
NCT01513733 |
Completed |
The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer |
|
- Drug: tasquinimod
- Drug: tasquinimod 0.25 mg; 0.5 mg
- Drug: tasquinimod 0.25 mg; 0.5 mg; 1.0 mg
|
Interventional
|
Phase 1 |
- Andrew J. Armstrong, MD
- Duke University
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants who experience dose limiting toxicities at the highest titrated dose for each dose level
- Evaluation of progression free survival
- Evaluation of overall response
- (and 7 more...)
|
25 |
Male |
18 Years to 79 Years (Adult, Older Adult) |
NCT01513733 |
Pro00032421
c11-082 |
CATCH |
January 2012 |
June 2015 |
June 2016 |
January 20, 2012 |
September 3, 2018 |
|
- The University of Chicago
Chicago, Illinois, United States - Duke Cancer Institute
Durham, North Carolina, United States
|
|
| 2 |
NCT03822494 |
Recruiting |
CyberKnife Dose Escalation Prostate Cancer Trial |
- Prostate Cancer
- Prostate Adenocarcinoma
- Prostate Neoplasm
|
- Radiation: CyberKnife SBRT
|
Interventional
|
Not Applicable |
- Crozer-Keystone Health System
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Bladder and Rectal Toxicity using NCI common toxicity criteria version 4.0
- Biochemical Disease Free Survival
- Duration of local control
- (and 4 more...)
|
100 |
Male |
18 Years and older (Adult, Older Adult) |
NCT03822494 |
PCK-02 |
CK-DESPOT |
July 12, 2018 |
July 12, 2023 |
July 12, 2028 |
January 30, 2019 |
January 30, 2019 |
|
- Crozer Keystone Health System/Philadelphia CyberKnife Center
Havertown, Pennsylvania, United States
|
|
| 3 |
NCT03541928 |
Recruiting |
Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery |
- High-risk Prostate Cancer
- Prostate Cancer
|
- Drug: HSV-Tk
- Drug: Valacyclovir
- Drug: Bicalutamide
- (and 3 more...)
|
Interventional
|
Phase 2 |
- The Methodist Hospital System
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Biochemical control rate
- Overall survival rate
- Pathologic complete response rate
- Safety based on questionnaire and clinical adverse event monitoring
|
60 |
Male |
18 Years and older (Adult, Older Adult) |
NCT03541928 |
Pro00017515 |
|
August 2, 2018 |
July 2023 |
July 2023 |
May 31, 2018 |
October 25, 2018 |
|
- Houston Methodist Hospital
Houston, Texas, United States
|
|
| 4 |
NCT01088529 |
Completed
Has Results |
Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer |
|
- Drug: Abiraterone Acetate
- Drug: Prednisone
- Drug: LHRHa
|
Interventional
|
Phase 2 |
- Cougar Biotechnology, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With a Pathology Tumor Stage of Less Than or Equal to Prostate Cancer Stage at Which the Tumor is Confined to the Prostate (pT2)
- Number of Participants With a Positive Surgical Margin at Radical Prostatectomy
- Number of Participants With Prostate-Specific Antigen Response
|
66 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01088529 |
CR016945
COU-AA-203 |
|
December 2009 |
March 2013 |
March 2013 |
March 17, 2010 |
May 15, 2014 |
April 9, 2014 |
- Houston, Texas, United States
|
|
| 5 |
NCT00214136 |
Completed
Has Results |
Intensity Modulated Radiation Therapy (IMRT) Radiotherapy for Treating Prostate Pelvic Nodes |
|
|
Interventional
|
Phase 2 |
- University of Wisconsin, Madison
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants Experiencing Expected Toxicities
- To Evaluate Local Tumor Control and Biochemical Progression-free and Metastasis-free Survival
|
30 |
Male |
18 Years and older (Adult, Older Adult) |
NCT00214136 |
RO04807
NCI-P01 CA88960 |
|
March 2005 |
March 2016 |
March 2016 |
September 21, 2005 |
October 12, 2017 |
October 12, 2017 |
- University Of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States
|
|
| 6 |
NCT03685448 |
Recruiting |
ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) |
- Renal Cell Carcinoma
- Papillary Renal Cell Carcinoma Type 1
- Papillary Renal Cell Carcinoma Type 2
- (and 3 more...)
|
|
Interventional
|
Phase 2 |
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The objective response rate (ORR), as assessed by RECIST 1.1.
- The number of participants with adverse events that are related to study drug, as assessed and graded by CTCAE v5.0.
- Progression-free survival (PFS), as assessed by RECIST1.1.
- The number of patients alive at the end of the study, as assessed by date of death. Overall survival (OS) is defined as the time between the date of registration to part 1 of the study and the date of death due to any cause.
|
48 |
All |
18 Years and older (Adult, Older Adult) |
NCT03685448 |
ANZUP1802 |
UNICAB |
April 11, 2019 |
April 30, 2022 |
April 30, 2024 |
September 26, 2018 |
April 12, 2019 |
|
- Border Medical Oncology Research Unit / The Border Cancer Hospital
Albury, New South Wales, Australia - St George Hospital
Kogarah, New South Wales, Australia - Macquarie University Hospital
Macquarie Park, New South Wales, Australia - (and 7 more...)
|
|
| 7 |
NCT03392428 |
Recruiting |
A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer |
- Cancer of the Prostate
- Metastatic Cancer
|
- Other: 177Lu-PSMA617
- Drug: Cabazitaxel
|
Interventional
|
Phase 2 |
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- Australian Nuclear Science and Technology Organisation (ANSTO)
- Endocyte
- (and 4 more...)
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Prostate Specific Antigen response rate (PSA RR)
- Pain Response (PPI and Analgesic Score)
- Objective Tumour Response Rate
- (and 7 more...)
|
200 |
Male |
18 Years and older (Adult, Older Adult) |
NCT03392428 |
ANZUP 1603 |
TheraP |
January 29, 2018 |
December 2020 |
January 2021 |
January 8, 2018 |
October 23, 2018 |
|
- Liverpool Hospital
Liverpool, New South Wales, Australia - St Vincent's Hospital
Sydney, New South Wales, Australia - Royal North Shore Hospital
Sydney, New South Wales, Australia - (and 8 more...)
|
|
| 8 |
NCT02156869 |
Completed |
Impact of a Printed Decision Aid on Patients' Intent to Undertake Prostate Cancer Screening |
|
|
Interventional
|
Not Applicable |
- University Paris 7 - Denis Diderot
- University of Paris 5 - Rene Descartes
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- patients' intent to undergo screening for prostate cancer
|
1170 |
Male |
50 Years to 75 Years (Adult, Older Adult) |
NCT02156869 |
DMG1 |
PSAMG |
November 2012 |
February 2013 |
June 2014 |
June 5, 2014 |
June 5, 2014 |
|
|
|
| 9 |
NCT03177239 |
Recruiting |
Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) |
- Renal Cell Carcinoma
- Papillary Renal Cell Carcinoma Type 1
- Papillary Renal Cell Carcinoma Type 2
- (and 3 more...)
|
- Drug: Nivolumab
- Drug: Ipilimumab
|
Interventional
|
Phase 2 |
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- Bristol-Myers Squibb
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The objective tumour response rate, as assessed by RECIST1.1
- Duration of objective tumour response, as assessed by RECIST1.1
- Progression-free survival (PFS), as assessed by RECIST1.1
- (and 5 more...)
|
85 |
All |
18 Years and older (Adult, Older Adult) |
NCT03177239 |
ANZUP 1602 |
UNISoN |
October 19, 2017 |
December 2021 |
December 2022 |
June 6, 2017 |
June 29, 2018 |
|
- Border Medical Oncology
Albury, New South Wales, Australia - Campbelltown Hospital
Campbelltown, New South Wales, Australia - Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia - (and 16 more...)
|
|
| 10 |
NCT03280667 |
Recruiting |
Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma |
- Renal Cell Carcinoma, Clear Cell
- Metastatic Kidney Cancer
|
- Drug: Pembrolizumab plus denosumab
|
Interventional
|
Phase 2 |
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- Merck Sharp & Dohme Corp.
- Amgen
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective tumour response
- Progression-free survival (PFS)
- Disease control rate (DCR)
- (and 4 more...)
|
70 |
All |
18 Years and older (Adult, Older Adult) |
NCT03280667 |
ANZUP1601
20149171
53963 |
KEYPAD |
December 12, 2017 |
April 4, 2021 |
October 4, 2021 |
September 12, 2017 |
March 25, 2019 |
|
- Northern Cancer Institute
Frenchs Forest, New South Wales, Australia - Calvary Mater Newcastle
Newcastle, New South Wales, Australia - Macquarie Cancer Clinical Trials
Sydney, New South Wales, Australia - (and 11 more...)
|
|
| 11 |
NCT02662062 |
Recruiting |
Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer |
|
- Drug: Pembrolizumab
- Drug: Cisplatin
- Radiation: Radiotherapy
|
Interventional
|
Phase 2 |
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- Peter MacCallum Cancer Centre, Australia
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of patients with grade 3 or 4 acute toxicities (excluding grade 3 or 4 urinary toxicities) that are related to study drug, graded according to CTCAE v4.03.
- The efficacy of the addition of pembrolizumab to concurrent chemoradiation regimen using the best response achieved, as assessed by cystoscopy at weeks 19 and 31 of the trial (12 and 24 weeks post completion of chemoradiotherapy).
- The number of patients to develop metastatic disease (i.e. the rate of metastatic disease), as assessed by CT scan.
- The number of patients having a salvage cystectomy (i.e. the rate of salvage cystectomy), as assessed by cystoscopy.
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT02662062 |
ANZUP 1502 |
PCR-MIB |
August 2016 |
September 2023 |
January 2024 |
January 25, 2016 |
February 8, 2018 |
|
- Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia - Prince of Wales Hospital
Randwick, New South Wales, Australia - Royal North Shore Hospital
St Leonards, New South Wales, Australia - (and 3 more...)
|
|
| 12 |
NCT02604225 |
Recruiting |
Trial of Methoxyflurane With Periprostatic Local Anaesthesia to Reduce the Discomfort of TRUS B |
|
- Drug: Methoxyflurane
- Drug: Placebo
|
Interventional
|
Phase 3 |
- University of Sydney
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Pain rated by participants will be self-rated using a numeric rating scale with verbal anchors from 0 (no trouble at all) to 10 (worst I can imagine).
- Other aspects of the biopsy experience rated by participants on the Patient's Experience of TRUS biopsy questionnaire.
- Willingness to undergo a biopsy in the future assessed by a questionnaire designed specifically for this study.
- (and 4 more...)
|
420 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02604225 |
ANZUP 1501
ACTRN12615001105538 |
TRUSB |
December 2015 |
September 2019 |
December 2019 |
November 13, 2015 |
May 9, 2018 |
|
- Concord Hospital
Concord, New South Wales, Australia - Australian Clinical Trials
Wahroonga, New South Wales, Australia - Casey Hospital
Berwick, Victoria, Australia - (and 4 more...)
|
|
| 13 |
NCT00860652 |
Active, not recruiting |
Radiotherapy - Adjuvant Versus Early Salvage |
|
- Radiation: Adjuvant Radiotherapy
- Radiation: Early Salvage Radiotherapy
|
Interventional
|
Phase 3 |
- Trans-Tasman Radiation Oncology Group (TROG)
- Urological Society of Australia and New Zealand (USANZ)
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- Trans-Tasman Radiation Oncology Group (TROG)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Biochemical failure: PSA ≥ 0.4 ng/ml and rising following RT
- Quality of Life
- Toxicity
- (and 9 more...)
|
333 |
Male |
18 Years and older (Adult, Older Adult) |
NCT00860652 |
TROG 08.03 |
RAVES |
March 2009 |
December 2021 |
December 2026 |
March 12, 2009 |
July 12, 2017 |
|
- Campbelltown Hopsital
Campbelltown, New South Wales, Australia - Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia - Coffs Harbour Health Campus, NCCI
Coffs Harbour, New South Wales, Australia - (and 33 more...)
|
|
| 14 |
NCT03079323 |
Recruiting |
Trial to Investigate the Benefit of Elective Para-Aortic Radiotherapy (PART) for pN1 Prostate Cancer |
|
|
Interventional
|
Phase 2 |
- Universitaire Ziekenhuizen Leuven
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical relapse-free survival (cRFS)
- Acute toxicity
- Late toxicity
- (and 11 more...)
|
137 |
Male |
18 Years and older (Adult, Older Adult) |
NCT03079323 |
S59533 |
PART |
February 6, 2017 |
February 1, 2025 |
February 1, 2025 |
March 14, 2017 |
November 19, 2018 |
|
|
|
| 15 |
NCT01982786 |
Unknown † |
Feasibility Trial Of Image Guided External Beam Radiotherapy With Or Without High Dose Rate Brachytherapy Boost In Men With Intermediate-Risk Prostate Cancer |
|
- Radiation: Image guided external beam radiotherapy with or without brachytherapy boost
- Radiation: Brachytherapy
|
Interventional
|
Phase 2 |
- Canadian Cancer Trials Group
- Canadian Cancer Trials Group
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Feasibility of ability to accrue patients
- Number of adverse events
- Treatment compliance
- Validation of a radiotherapy quality assurance process
|
57 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01982786 |
PR15 |
|
November 5, 2013 |
March 2016 |
May 2017 |
November 13, 2013 |
March 24, 2017 |
|
- Dr. H. Bliss Murphy Cancer Centre
St. John's, Newfoundland and Labrador, Canada - Royal Victoria Regional Health Centre
Barrie, Ontario, Canada - Lakeridge Health Oshawa
Oshawa, Ontario, Canada - (and 6 more...)
|
|
| 16 |
NCT02033993 |
Unknown † |
Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients With Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen. |
|
- Drug: Nab-Paclitaxel
- Drug: Paclitaxel
|
Interventional
|
Phase 2 |
- Canadian Cancer Trials Group
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- Celgene
- Canadian Cancer Trials Group
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-Free Survival
- Overall Survival
- Clinical Benefit Rate
- (and 4 more...)
|
199 |
All |
18 Years and older (Adult, Older Adult) |
NCT02033993 |
BL12 |
|
January 27, 2014 |
January 11, 2018 |
September 2018 |
January 13, 2014 |
February 1, 2018 |
|
- Townsville Hospital
Douglas, Queensland, Australia - Nambour General Hospital
Nambour, Queensland, Australia - Flinders Medical Centre
Bedford Park, South Australia, Australia - (and 34 more...)
|
|
| 17 |
NCT02948543 |
Recruiting |
Adding Mitomycin C to Bacillus of Calmette-Guerin (BCG) as Adjuvant Intravesical Therapy for High-risk, Non-Muscle-invasive Bladder Cancer |
|
- Biological: Bacillus of Calmette-Guerin (BCG)
- Drug: Mitomycin C (MMC)
|
Interventional
|
Phase 3 |
- University of Sydney
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- Cancer Australia
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease free survival (death or recurrence)
- Activity (Clear cystoscopy at 3 months)
- Time to recurrence (recurrence)
- (and 6 more...)
|
500 |
All |
18 Years and older (Adult, Older Adult) |
NCT02948543 |
ANZUP 1301
12613000513718 |
BCG+MMC |
July 2013 |
December 2020 |
December 2020 |
October 28, 2016 |
May 9, 2018 |
|
- Concord Repatriation General Hospital
Concord, New South Wales, Australia - Northern Cancer Institute, St Leonards
St Leonards, New South Wales, Australia - The Tweed Hospital
Tweed Heads, New South Wales, Australia - (and 7 more...)
|
|
| 18 |
NCT00489060 |
Completed |
A Randomized Trial of External Beam Radiotherapy Versus Cryoablation in Patients With Localized Prostate Cancer |
|
- Procedure: Cryoablation and External Beam Radiation
|
Interventional
|
Phase 3 |
- University of Calgary
- Canadian Cancer Trials Group
- AHS Cancer Control Alberta
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- No evidence of disease progression (NEDP) at 36 months
- Prostate biopsy status
|
244 |
Male |
Child, Adult, Older Adult |
NCT00489060 |
9716 |
|
December 1997 |
|
April 2007 |
June 21, 2007 |
July 17, 2008 |
|
- Tom Baker Cancer Center
Calgary, Alberta, Canada
|
|
| 19 |
NCT03423303 |
Enrolling by invitation |
A Randomized Trial of Early Detection of Clinically Significant Prostate Cancer (ProScreen) |
|
- Diagnostic Test: Prostate cancer screening
|
Interventional
|
Not Applicable |
- Tampere University
- Helsinki University Hospital, Finland
- Tampere University Hospital, Finland
- (and 8 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Prostate cancer (PrCa) mortality
- Prostate cancer (PrCa) mortality - secondary analysis
- Cumulative incidence of advanced (T3-T4 or M1) prostate cancer
- Cumulative incidence of low-risk cancer (Gleason<7)
|
11056 |
Male |
50 Years to 63 Years (Adult) |
NCT03423303 |
2910/2017 |
ProScreen |
April 23, 2018 |
December 31, 2028 |
December 31, 2028 |
February 6, 2018 |
May 3, 2018 |
|
- Helsinki University and Helsinki University Hospital
Helsinki, Finland - University of Tampere
Tampere, Finland
|
|
| 20 |
NCT02446405 |
Active, not recruiting |
Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer |
|
- Drug: Enzalutamide
- Drug: NSAA
- Drug: LHRHA or Surgical Castration
|
Interventional
|
Phase 3 |
- University of Sydney
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- National Health and Medical Research Council, Australia
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival Time
- Prostate specific antigen progression free survival time
- Clinical progression free survival time
- (and 3 more...)
|
1125 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02446405 |
ANZUP 1304
ACTRN12614000110684 |
ENZAMET |
March 2014 |
September 2020 |
December 2020 |
May 18, 2015 |
May 3, 2018 |
|
- Dana Farber Cancer Institute
Boston, Massachusetts, United States - Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia - Coffs Harbour Health Campus
Coffs Harbour, New South Wales, Australia - (and 79 more...)
|
|
| 21 |
NCT02446444 |
Active, not recruiting |
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer |
|
- Drug: Enzalutamide
- Drug: Conventional NSAA
- Drug: LHRHA
- Radiation: External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost)
|
Interventional
|
Phase 3 |
- University of Sydney
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- National Health and Medical Research Council, Australia
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival time
- Cause-specific survival time
- Prostate Specific Antigen (PSA) progression free survival time
- (and 7 more...)
|
802 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02446444 |
ANZUP1303
ACTRN12614000126617 |
ENZARAD |
March 2014 |
September 2021 |
December 2021 |
May 18, 2015 |
July 6, 2018 |
|
- Dana Farber Cancer Institute
Boston, Massachusetts, United States - Beth Israel Deaconness Medical Center
Boston, Massachusetts, United States - Blacktown Hospital
Blacktown, New South Wales, Australia - (and 66 more...)
|
|
| 22 |
NCT01658527 |
Withdrawn |
TAK-700 in Castration Resistant Prostate Cancer |
|
- Drug: Orteronel
- Drug: Bicalutamide
|
Interventional
|
Phase 2 |
- European Organisation for Research and Treatment of Cancer - EORTC
- European Organisation for Research and Treatment of Cancer - EORTC
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary endpoint of the trial is clinical progression free survival.
- RECIST (Response Evaluation Criteria In Solid Tumors) response in patients presenting with measurable disease
- Time to PSA (Prostate specific antigen) progression and PSA change from baseline
- (and 4 more...)
|
0 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01658527 |
EORTC-1211-GUCG-IG
2012-002122-67 |
|
January 2014 |
January 2016 |
January 2017 |
August 7, 2012 |
June 10, 2016 |
|
- Onze Lieve Vrouw Ziekenhuis
Aals, Belgium - Cliniques Universitaires Saint-Luc
Brussels, Belgium - AZ Groeninge Kortrijk - Campus Vercruysselaan
Kortrijck, Belgium - CHU Dinant Godinne - UCL Namur
Yvoir, Belgium
|
|
| 23 |
NCT02079025 |
Completed
Has Results |
Multi-Center Trial of High-resolution Transrectal Ultrasound Versus Standard Low-resolution Transrectal Ultrasound for the Identification of Clinically Significant Prostate Cancer |
- Prostatic Neoplasms
- Prostate Cancer
- Cancer of the Prostate
|
- Device: High-resolution ultrasound guided prostate biopsy
- Device: Standard ultrasound guided prostate biopsy
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Percentage of Participants With Clinically Significant Prostate Cancer
- Improvement of an Investigator's Ability to Detect Clinically Significant Cancer Using UHR-TRUS Post-training When Compared to Pre-training
- Combined Sensitivity and Specificity in Determining Cancer Detection Overall for Image-guided Biopsy
|
1676 |
Male |
40 Years to 79 Years (Adult, Older Adult) |
NCT02079025 |
2013-UHR-002 |
|
December 2013 |
December 2016 |
February 2018 |
March 5, 2014 |
February 26, 2019 |
January 8, 2019 |
- Johns Hopkins Brady Urological Institution
Baltimore, Maryland, United States - Urology of Virgina
Virginia Beach, Virginia, United States - Prostate Cancer Centre
Calgary, Alberta, Canada - (and 2 more...)
|
|
| 24 |
NCT01242748 |
Terminated
Has Results |
A Degarelix Trial in Patients With Prostate Cancer |
|
- Drug: Degarelix
- Drug: Goserelin acetate
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Hazard Ratio of Prostate-specific Antigen (PSA) Progression-free Survival (PFS) Failure Rates During 3 Years' Treatment Between Degarelix and Goserelin
- Hazard Ratio of PFS Failure Rates During 3 Years Treatment Between Degarelix and Goserelin
- Hazard Ratio of PSA Failure Rates During 3 Years Treatment Between Degarelix and Goserelin
- (and 5 more...)
|
288 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01242748 |
FE200486 CS35A
2010-021434-55 |
|
October 2010 |
December 2011 |
January 2012 |
November 17, 2010 |
June 3, 2015 |
June 3, 2015 |
- University of Colorado School of Medicine
Aurora, Colorado, United States - The Urology Center of Colorado
Denver, Colorado, United States - Urology Associates of Dover, PA
Dover, Delaware, United States - (and 60 more...)
|
|
| 25 |
NCT02470936 |
Completed |
Web-based Lifestyle Trial Among Men With Prostate Cancer: Prostate 8 |
|
- Behavioral: Lifestyle intervention
|
Interventional
|
Not Applicable |
- University of California, San Francisco
- American Cancer Society, Inc.
- Prostate Cancer Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Fitbit use
- text message use
- website use - number of days the website was visited
- (and 18 more...)
|
76 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02470936 |
14-13555 |
Prostate 8 |
June 2015 |
June 2017 |
March 2018 |
June 12, 2015 |
February 22, 2019 |
|
- University of California, San Francisco (UCSF)
San Francisco, California, United States
|
|
| 26 |
NCT02906241 |
Recruiting |
PACCT: Partnering Around Cancer Clinical Trials |
|
- Behavioral: Patients: Questions to Ask Your Doctor: A Workbook for Patient-Doctor Teams
- Behavioral: Physicians: Educational Module
|
Interventional
|
Not Applicable |
- Susan Eggly
- National Cancer Institute (NCI)
- Barbara Ann Karmanos Cancer Institute
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Patient decisions to enroll in a trial
- Physician offers of a clinical trial
- Patient Active Participation
- (and 5 more...)
|
464 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02906241 |
2016-098
R01CA200718-01 |
|
September 2016 |
May 2021 |
May 2021 |
September 20, 2016 |
December 13, 2018 |
|
- Johns Hopkins University/Sidney Kimmel Comprehensive Cancer
Baltimore, Maryland, United States - Karmanos Cancer Institute
Detroit, Michigan, United States
|
|
| 27 |
NCT01300104 |
Completed |
Feasibility Study on a Nordic Lifestyle Intervention Trial Among Men With Prostate Cancer |
|
- Behavioral: Exercise
- Behavioral: Whole grain rye
- Behavioral: Recommendations
|
Interventional
|
Not Applicable |
- Danish Cancer Society
- Aarhus University Hospital
- University of Aarhus
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Feasibility of a planned Nordic life style intervention
- Prostate cancer progression, effect of the life style intervention
- Insulin sensitivity and insulin secretion, effect of the life style intervention
- (and 3 more...)
|
24 |
Male |
55 Years to 70 Years (Adult, Older Adult) |
NCT01300104 |
EC Grant agreement 242244
CHANCES |
|
February 2011 |
February 2015 |
February 2015 |
February 21, 2011 |
February 19, 2015 |
|
- Aarhus University, Institute of Sport Science
Aarhus, Denmark - Counseling Center, Danish Cancer Society
Aarhus, Denmark - Aarhus University Hospital Skejby
Aarhus, Denmark - Danish Cancer Society
Copenhagen, Denmark
|
|
| 28 |
NCT02960087 |
Recruiting |
Phase II High Dose Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer |
|
- Radiation: Low dose rate brachytherapy
- Radiation: High dose rate brachytherapy
|
Interventional
|
Phase 2 |
- Canadian Cancer Trials Group
- Canadian Cancer Trials Group
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Efficacy of HDR and LDR brachytherapy on prostate cancer control as defined by 48 month PSA values
- Disease-free survival
- Number and severity of adverse events
- (and 2 more...)
|
232 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02960087 |
PR19 |
|
November 4, 2016 |
November 2023 |
May 2024 |
November 9, 2016 |
April 10, 2019 |
|
- Odette Cancer Centre
Toronto, Ontario, Canada - University Health Network
Toronto, Ontario, Canada - Windsor Regional Cancer Centre
Windsor, Ontario, Canada - (and 3 more...)
|
|
| 29 |
NCT03869762 |
Recruiting |
Phase II Study of Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases. |
- Castration-resistant Prostate Cancer
- Metastatic Cancer
- Bone Metastases
|
|
Interventional
|
Phase 2 |
- Cancer Trials Ireland
- Cancer Trials Ireland
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Radiographic progression free survival (rPFS)
- Overall survival
- PSA progression free survival
- (and 2 more...)
|
88 |
Male |
18 Years and older (Adult, Older Adult) |
NCT03869762 |
CTRIAL-IE 17-17 |
DICE |
January 9, 2019 |
January 2023 |
March 2024 |
March 11, 2019 |
March 11, 2019 |
|
- Galway University Hospital
Galway, Connacht, Ireland - Sligo University Hospital
Sligo, Connacht, Ireland - Adelaide and Meath incorporating National Children's Hopsital
Dublin 24, Leinster, Ireland - (and 4 more...)
|
|
| 30 |
NCT00002540 |
Active, not recruiting
Has Results |
Screening for Prostate Cancer in Older Patients (PLCO Screening Trial) |
|
- Other: Laboratory Biomarker Analysis
- Procedure: Medical Examination
- Other: Screening Questionnaire Administration
|
Interventional
|
Not Applicable |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Screening
|
- Prostate Cancer Deaths
- Prostate Cancer Death Rates
- Deaths From All Causes
- (and 14 more...)
|
76685 |
Male |
55 Years to 74 Years (Adult, Older Adult) |
NCT00002540 |
NCI-2012-01755
PLCO-1
CDR0000078532
PLCO-Prostate
NCI-P93-0050 |
|
November 16, 1993 |
May 21, 2012 |
|
March 26, 2004 |
February 25, 2019 |
June 26, 2014 |
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
|
| 31 |
NCT02914873 |
Recruiting |
SPCG17: Prostate Cancer Active Surveillance Trigger Trial |
|
- Procedure: Active surveillance
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival
- Cumulative incidence of pT3 at radical prostatectomy specimens
- Cumulative incidence of metastases
- (and 3 more...)
|
2000 |
Male |
Child, Adult, Older Adult |
NCT02914873 |
SPCG-17 |
PCASTT |
October 2016 |
December 2030 |
December 2030 |
September 26, 2016 |
October 29, 2018 |
|
- Helsinki University Hospital
Helsinki, Finland - St Olavs University Hospital
Trondheim, Norway - Hospital of Vestfold
Tønsberg, Norway - (and 9 more...)
|
|
| 32 |
NCT02678520 |
Withdrawn |
Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients |
|
- Radiation: 3-D Conformal Radiation Therapy
- Radiation: Intensity Modulated Radiation Therapy
- Drug: Casodex, Zoladex , Lupron
|
Interventional
|
Phase 2 |
- University of Kansas Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
|
- Acute rectal, bladder and other toxicity rates - For participants 1 through 10 in each treatment arm
- Acute rectal, bladder and other toxicity rates - For all 100 study participants
- Dose Volume Histogram (DVH) dose quantification and comparison
- (and 2 more...)
|
0 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02678520 |
2015-IIT-RT-IMRT |
|
December 2015 |
February 2016 |
February 2016 |
February 9, 2016 |
July 22, 2016 |
|
- The University of Kansas Cancer Center (KUCC)
Fairway, Kansas, United States
|
|
| 33 |
NCT00949338 |
Completed |
Comparing Two Sets of Bladder-Filling Instructions in Treating Patients Undergoing Radiation Therapy For Prostate Cancer. ICORG 05-04 |
|
- Procedure: pre-procedural preparation
|
Interventional
|
Not Applicable |
- Cancer Trials Ireland
- Cancer Trials Ireland
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Consistency of bladder volumes
- Incidence of acute and late genitourinary and gastrointestinal toxicity
- Patient satisfaction with bladder-filling instructions
- Staff satisfaction of bladder-filling protocols
|
183 |
Male |
18 Years and older (Adult, Older Adult) |
NCT00949338 |
05-04 ICORG
ICORG-05-04
EU-20923 |
|
March 2006 |
June 2010 |
|
July 30, 2009 |
December 31, 2014 |
|
- Saint Luke's Radiation Oncology Network
Dublin, Ireland
|
|
| 34 |
NCT03784755 |
Not yet recruiting |
Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer |
- Prostate Cancer Metastatic
|
- Radiation: Ablative Radiation Therapy
- Other: Standard of care
|
Interventional
|
Phase 3 |
- Canadian Cancer Trials Group
- TerSera Therapeutics
- Canadian Cancer Society Research Institute (CCSRI)
- Canadian Cancer Trials Group
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Failure-free Survival
- Radiographic Progression-free Survival
- Incidence of new metastases as first event
- (and 7 more...)
|
410 |
Male |
18 Years and older (Adult, Older Adult) |
NCT03784755 |
PR20 |
PLATON |
March 31, 2019 |
July 2025 |
December 2025 |
December 24, 2018 |
March 13, 2019 |
|
|
|
| 35 |
NCT03506997 |
Recruiting |
Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer |
- Castration-resistant Prostate Cancer
|
|
Interventional
|
Phase 2 |
- Institute of Cancer Research, United Kingdom
- Merck Sharp & Dohme Corp.
- Institute of Cancer Research, United Kingdom
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To evaluate tumour response
- Radiological progression-free survival (rPFS)
- Time to radiological progression
- (and 5 more...)
|
100 |
Male |
18 Years and older (Adult, Older Adult) |
NCT03506997 |
ICR-CTSU/2016/10060
2017-000931-15 |
PERSEUS1 |
November 27, 2018 |
September 1, 2023 |
September 1, 2025 |
April 24, 2018 |
December 24, 2018 |
|
- The Royal Marsden Hospital
Sutton, Surrey, United Kingdom
|
|
| 36 |
NCT00265070 |
Completed |
Trial of Iressa in Prostate Cancer Patients |
|
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary objective of the trial is to evaluate the activity of oral ZD1839 (250 mg once daily administered continuously) in subjects with early biochemical failure post prostatectomy by estimating the PSA response rate
- To estimate the duration of PSA response
- To estimate the partial PSA response rate
- (and 2 more...)
|
80 |
Male |
18 Years and older (Adult, Older Adult) |
NCT00265070 |
1839IL/0093 |
|
January 2003 |
|
August 2011 |
December 14, 2005 |
February 5, 2013 |
|
- Research Site
Vancouver, British Columbia, Canada - Research Site
London, Ontario, Canada - Research Site
Toronto, Ontario, Canada - Research Site
Montreal, Canada
|
|
| 37 |
NCT02435472 |
Recruiting |
Active Surveillance Exercise Clinical Trial |
- Localized Prostate Cancer
- Active Surveillance for Prostate Cancer
|
|
Interventional
|
Not Applicable |
- University of California, San Francisco
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Genomic signature changes
- mRNA expression patterns in tumor and surrounding stromal (normal) tissue
- Effect of aerobic training on general anxiety
- (and 2 more...)
|
150 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02435472 |
135512 |
ASX |
May 2016 |
April 2020 |
April 2025 |
May 6, 2015 |
June 6, 2018 |
|
- University of CA San Francisco
San Francisco, California, United States
|
|
| 38 |
NCT03618355 |
Recruiting |
Trial of eRapa in Prostate Cancer Patients |
|
- Drug: eRapa (encapsulated rapamycin)
|
Interventional
|
Phase 1 |
- Rapamycin Holdings, Inc. dba Emtora Biosciences
- Cancer Insight, LLC
- Rapamycin Holdings Inc.
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Primary Safety and Tolerability (Incidence of Treatment-Emergent Adverse Events)
- Secondary Pharmacokinetics: AUC
- Secondary Pharmacokinetics: Exposure Trough Levels
- (and 11 more...)
|
24 |
Male |
18 Years and older (Adult, Older Adult) |
NCT03618355 |
RHI-P01 |
|
July 20, 2018 |
August 15, 2019 |
August 15, 2019 |
August 7, 2018 |
May 10, 2019 |
|
- UT Health San Antonio
San Antonio, Texas, United States
|
|
| 39 |
NCT00695851 |
Completed |
Dose-Seeking Trial of PCK3145 in Asymptomatic, Castrate Metastatic Prostate Cancer Patients. |
|
|
Interventional
|
Phase 1 |
- Memorial Sloan Kettering Cancer Center
- Ambrilia Biopharma, Inc.
- Memorial Sloan Kettering Cancer Center
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To explore the PK profiles and their association with two dosing schedules of PCK3145 given iv bolus in patients with asymptomatic castrate metastatic prostate cancer.
- To explore the association of 2 dosing schedules of PCK3145 with MMP-9 levels in asymptomatic pts with castrate metastatic prostate cancer. The results of this analysis will be used to establish a dose on which to build a phase II randomized trial.
- To assess the safety and toxicity of PCK3145 at a dose of 150mg/m² i.v. bolus given weekly for 16 weeks.
|
36 |
All |
18 Years and older (Adult, Older Adult) |
NCT00695851 |
05-019 |
|
March 2005 |
March 2009 |
March 2009 |
June 12, 2008 |
March 30, 2009 |
|
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
|
|
| 40 |
NCT03162003 |
Active, not recruiting |
Irish Programme for Stratified Prostate Cancer Therapy |
|
|
Observational
|
|
- Cancer Trials Ireland
- Cancer Trials Ireland
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Biomarkers of Androgen Deprivation Therapy (ADT) alone and combined.
- Biomarkers to treatment response
- Circulating Tumour Cells (CTC's)
|
55 |
Male |
18 Years and older (Adult, Older Adult) |
NCT03162003 |
CTRIAL-IE (ICORG) 14-04 |
iPROSPECT |
February 2015 |
February 2024 |
February 2025 |
May 22, 2017 |
July 24, 2018 |
|
- Cork University Hospital, Wilton road
Cork, Ireland - Mater Misericordiae University Hospital & Mater Private Hospital
Dublin 7, Ireland - St James's Hospital, James's street
Dublin 8, Ireland - (and 6 more...)
|
|
| 41 |
NCT00831467 |
Completed |
Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease |
- Hormonal Refractory Prostate Cancer
|
|
Interventional
|
Phase 1
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determination of the recommended dose for exploration in the phase II part
- Assessment of Safety of trial regimen
|
48 |
Male |
18 Years to 75 Years (Adult, Older Adult) |
NCT00831467 |
CV-9103-001 |
|
January 2009 |
December 2009 |
September 2013 |
January 29, 2009 |
March 20, 2018 |
|
- Universitätsklinikum Aachen, Urologische Klinik
Aachen, Germany - Charité Universitätsmedizin Berlin, Urologische Klinik u. Hochschulambulanz
Berlin, Germany - Universitätsklinikum Carl Gustav Carus der TU Dresden, Klinik und Poliklinik für Urologie
Dresden, Germany - (and 9 more...)
|
|
| 42 |
NCT02024685 |
Terminated |
Treatment Decision Analysis Model for Prostate Cancer: A Randomized Trial |
- Adenocarcinoma of Prostate
- Adenocarcinoma of the Prostate Stage I
- Adenocarcinoma of the Prostate Stage II
- Adenocarcinoma of the Prostate Stage III
|
- Behavioral: Personalized Treatment Recommendations
- Behavioral: Standard patient-physician counseling interaction
|
Interventional
|
Not Applicable |
- Case Comprehensive Cancer Center
- Case Comprehensive Cancer Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Decisional regret
- Decisional conflict
- Treatment satisfaction
- Current health state utility
|
76 |
Male |
Child, Adult, Older Adult |
NCT02024685 |
CASE19806
NCI-2013-02363 |
|
August 2013 |
May 2014 |
May 2014 |
December 31, 2013 |
November 10, 2015 |
|
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
|
|
| 43 |
NCT00176644 |
Terminated
Has Results |
Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer |
|
- Drug: Transdermal Estradiol
|
Interventional
|
Phase 2 |
- University of Medicine and Dentistry of New Jersey
- National Cancer Institute (NCI)
- Rutgers, The State University of New Jersey
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To Evaluate the Antitumor Activity, as Measured by PSA Response Rate in Patients With Hormone and Chemotherapy Refractory Prostate Cancer.
- To Measure Quality of Life of Patients Receiving Therapy With the Functional Assessment of Cancer Therapy-Prostate Scale (FACT-P).
- To Evaluate Measurable Disease Response in Patients With Hormone and Chemotherapy Refractory Prostate Cancer.
- (and 2 more...)
|
23 |
Male |
18 Years and older (Adult, Older Adult) |
NCT00176644 |
CDR0000445280
CINJ 080419
P30CA072720 |
|
May 2005 |
December 2008 |
December 2008 |
September 15, 2005 |
December 24, 2013 |
December 24, 2013 |
- CentraState Healthcare System
Freehold, New Jersey, United States - Robert Wood Johnson University Hospital/CINJ at Hamilton
Hamilton, New Jersey, United States - Morristown Memorial Hospital
Morristown, New Jersey, United States - (and 3 more...)
|
|
| 44 |
NCT02015871 |
Completed |
An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate Cancer |
|
|
Interventional
|
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number and percentage of patients with Adverse Events (AEs)
- Change in ECG parameters
- Change in body weight and vital signs
- (and 4 more...)
|
206 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02015871 |
000006A |
PandaExtension |
January 2014 |
August 1, 2017 |
August 1, 2017 |
December 19, 2013 |
August 22, 2017 |
|
- Peking University People's Hospital (there may be multiple sites in this country)
Beijing, Beijing, China
|
|
| 45 |
NCT01510288 |
Terminated |
Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer |
|
- Drug: GVAX and ipilimumab
|
Interventional
|
Phase 1 |
- VU University Medical Center
- Cell Genesys
- Medarex
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of patients with adverse events
- number of patients that have a tumor/PSA response
- number of patients that will develop a tumor-specific (e.g. PSMA, NY-ESO) antibody response as measured by ELISA
- the number of patients that have activated T cells and dendritic cells as measured by FACS
|
28 |
Male |
18 Years to 80 Years (Adult, Older Adult) |
NCT01510288 |
G-0016 |
|
November 2004 |
December 2007 |
November 2011 |
January 16, 2012 |
January 16, 2012 |
|
- VU university medical center
Amsterdam, Netherlands
|
|
| 46 |
NCT03449719 |
Not yet recruiting |
Phase II Randomized Trial of Radiation Therapy in Oligometastatic mCRPC Prostate Cancer (ARTO) |
- Rate of PSA Response in Oligometastatic,CRPC Undergoing SBRT in Combination With Abiraterone Acetate (AA), Compared to Patients Treated With AA Alone
|
- Radiation: SBRT - Ablative radiation Therapy
- Drug: Abiraterone Acetate
|
Interventional
|
Not Applicable |
- Lorenzo Livi
- Azienda Ospedaliero-Universitaria Careggi
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
174 |
Male |
Child, Adult, Older Adult |
NCT03449719 |
ARTO |
ARTO |
May 1, 2018 |
September 1, 2021 |
May 1, 2022 |
February 28, 2018 |
February 28, 2018 |
|
|
|
| 47 |
NCT03358563 |
Recruiting |
Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer |
|
- Drug: Docetaxel
- Drug: Degarelix
- Drug: Bicalutamide
|
Interventional
|
Early Phase 1 |
- University of Wisconsin, Madison
- United States Department of Defense
- National Cancer Institute (NCI)
|
Other / U.S. Fed / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in pCR rates
- Change in PSA
- PSA Recurrence
- Safety and tolerability of combination ADT and docetaxel measured by CTCAE v.4.0
|
30 |
Male |
18 Years and older (Adult, Older Adult) |
NCT03358563 |
UW17009
P30CA014520
2017-0606 |
|
January 5, 2018 |
July 1, 2020 |
January 1, 2021 |
November 30, 2017 |
March 21, 2019 |
|
- University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
|
|
| 48 |
NCT02423928 |
Recruiting |
Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer |
|
- Biological: Dendritic cell based cryoimmunotherapy
- Drug: Cyclophosphamide
- Drug: ipilimumab
|
Interventional
|
Phase 1 |
- Alden Cancer Therapy II
- Haukeland University Hospital
- Norwegian Radium Hospital
- Alden Cancer Therapy II
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Composite measure of the safety and toxicity profile, including definition of the Maximum Tolerated Dose.
|
20 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02423928 |
ACT2001
2014-001898-14 |
CryoIT |
May 2015 |
December 2018 |
April 2019 |
April 22, 2015 |
June 28, 2018 |
|
- Haukeland University Hospital Research Department
Bergen, Hordaland, Norway
|
|
| 49 |
NCT03040791 |
Recruiting |
Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial) |
|
|
Interventional
|
Phase 2 |
- Hospital Moinhos de Vento
- Bristol-Myers Squibb
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- PSA response rate
- Time to PSA progression
- PSA Response Rate at 6 and 12 months
- (and 4 more...)
|
29 |
Male |
18 Years and older (Adult, Older Adult) |
NCT03040791 |
64121317.4.1001.5330 |
ImmunoProst |
June 1, 2018 |
July 1, 2019 |
July 1, 2019 |
February 2, 2017 |
July 31, 2018 |
|
- Hospital Moinhos de Vento
Porto Alegre, Rio Grande Do Sul, Brazil - Instituto do Câncer do Estado de São Paulo
Sao Paulo, São Paulo, Brazil
|
|
| 50 |
NCT00447473 |
Terminated |
Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer |
|
- Drug: GM-CSF
- Drug: Ketoconazole
- Drug: Mitoxantrone
|
Interventional
|
Phase 2 |
- The Methodist Hospital System
- Bayer
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To evaluate the effect of the combination of ketoconazole and mitoxantrone plus GM-CSF on time to clinical progression in patients with prostate cancer that has progressed on prior therapy.
- To evaluate the objective response frequency of the combination of ketoconazole and mitoxantrone plus GM-CSF.
- To investigate the safety of ketoconazole and mitoxantrone given in combination with GM-CSF.
|
31 |
Male |
18 Years and older (Adult, Older Adult) |
NCT00447473 |
HMRI IRB#0106-0010
PC-Keto-Mito.2006 |
|
July 2006 |
August 2008 |
September 2008 |
March 14, 2007 |
March 17, 2016 |
|
- Baylor College of Medicine - Methodist Hospital
Houston, Texas, United States
|
|
| 51 |
NCT03655886 |
Recruiting |
Cytoreductive Prostatectomy Versus Cytoreductive Prostate Irradiation as a Local Treatment Option for Metastatic Prostate Cancer: a Multicentric Feasibility Trial |
- Prostate Cancer Metastatic
|
- Procedure: radical prostatectomy
- Radiation: Whole pelvis radiotherapy
|
Interventional
|
Phase 2 |
- University Hospital, Ghent
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Feasibility of randomization between both treatment arms as assessed by the randomized proportion
- castration-resistant free survival
|
86 |
Male |
18 Years and older (Adult, Older Adult) |
NCT03655886 |
B670201835086 |
LoMP II |
August 15, 2018 |
August 1, 2020 |
August 1, 2022 |
August 31, 2018 |
August 31, 2018 |
|
- University Hospital Ghent
Ghent, Belgium
|
|
| 52 |
NCT01709734 |
Completed |
A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer |
|
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Confirmation of recommended dose and patient population for Part 2 of the study.
- Assessment of efficacy by means of PSA response.
|
126 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01709734 |
TOK-200-10 |
ARMOR2 |
December 2012 |
September 2016 |
September 2016 |
October 18, 2012 |
August 3, 2018 |
|
- UCLA David Geffen School of Medicine
Los Angeles, California, United States - San Bernardino Urological Associates
San Bernardino, California, United States - Raton Regional Hospital, Lynn Cancer Institute
Boca Raton, Florida, United States - (and 20 more...)
|
|
| 53 |
NCT03110588 |
Recruiting |
Phase I Trial of PACE for Metastatic Prostate Cancer |
- Metastatic Prostate Cancer
|
- Drug: PACE with Cabazitaxel (15 mg/m2)
- Drug: PACE with Cabazitaxel (20 mg/m2)
|
Interventional
|
Phase 1 |
- University of Alabama at Birmingham
- Astellas Pharma Inc
- Sanofi
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose of PACE as first-line therapy
- Prostate specific antigen (PSA)
- Radiographic progression-free survival with PACE
- (and 3 more...)
|
12 |
Male |
18 Years and older (Adult, Older Adult) |
NCT03110588 |
F161215003 (UAB 1663) |
|
July 1, 2018 |
August 1, 2021 |
August 1, 2023 |
April 12, 2017 |
August 1, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States
|
|
| 54 |
NCT02799706 |
Recruiting |
Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer |
|
- Drug: Degarelix
- Drug: approved GnRH agonist
- Radiation: Radiotherapy
|
Interventional
|
Phase 3 |
- European Organisation for Research and Treatment of Cancer - EORTC
- European Organisation for Research and Treatment of Cancer - EORTC
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival
- Clinical progression-free survival
- Time to next systemic anticancer therapy (including secondary hormonal manipulation)
- (and 4 more...)
|
885 |
Male |
18 Years to 80 Years (Adult, Older Adult) |
NCT02799706 |
EORTC-1414 |
PEGASUS |
September 25, 2017 |
June 2024 |
June 2024 |
June 15, 2016 |
July 20, 2018 |
|
- Hopitaux Universitaires Bordet-Erasme - Hopitaux Universitaires Bordet- Institut Jules Bordet
Brussels, Belgium - Hopitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme
Brussels, Belgium - Cliniques Universitaires Saint-Luc
Brussels, Belgium - (and 17 more...)
|
|
| 55 |
NCT02703623 |
Recruiting |
A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO) |
|
- Drug: Abiraterone acetate
- Drug: Prednisone
- Drug: ARN509
- (and 3 more...)
|
Interventional
|
Phase 2 |
- M.D. Anderson Cancer Center
- Bristol-Myers Squibb
- Janssen, LP
- (and 2 more...)
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival (OS) of Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) to the Bone Who Have a Satisfactory Decline in Serum Markers
- Overall Survival (OS) of Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) to the Bone Who Have a Unsatisfactory Decline in Serum Markers
- Toxicity Profile of Study Drug Combinations
- (and 2 more...)
|
265 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02703623 |
2014-0386
NCI-2016-00670 |
|
May 2016 |
May 2020 |
May 2020 |
March 9, 2016 |
May 3, 2019 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 56 |
NCT00246753 |
Completed
Has Results |
Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy |
|
- Drug: lapatinib ditosylate
|
Interventional
|
Phase 2 |
- UNC Lineberger Comprehensive Cancer Center
- GlaxoSmithKline
- UNC Lineberger Comprehensive Cancer Center
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Patients Experiencing Decline in Prostate-specific Antigen
- Time to Prostate-Specific Antigen (PSA) Progression
- Predictive Molecular Markers of Response to Treatment With Lapatinib (GW572016)
|
29 |
Male |
18 Years and older (Adult, Older Adult) |
NCT00246753 |
LCCC 0505
CDR0000550151 |
NRR |
October 2005 |
July 2012 |
May 2013 |
October 31, 2005 |
June 28, 2017 |
June 28, 2017 |
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, United States - Duke Comprehensive Cancer Center
Durham, North Carolina, United States - Rex Cancer Center at Rex Hospital
Raleigh, North Carolina, United States
|
|
| 57 |
NCT01942837 |
Active, not recruiting |
Phase II Trial of Enzalutamide for CRPC With Correlative Assessment of Androgen Receptor Signaling |
|
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Medivation, Inc.
- Dana-Farber Cancer Institute
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To analyze possible Androgen Receptor (AR) related mechanisms of resistance to enzalutamide in serial Castration resistant prostate cancer (CRPC) biopsies
- Assess changes in serum androgen concentrations (including testosterone, dihydrotestosterone (DHT), and androgen precursors) between baseline and subsequent assessment visits.
- To assess prostate specific antigen (PSA) response to enzalutamide
- (and 5 more...)
|
66 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01942837 |
13-301 |
|
September 2013 |
December 2019 |
July 2022 |
September 16, 2013 |
May 6, 2019 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States - Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States - (and 2 more...)
|
|
| 58 |
NCT02747342 |
Active, not recruiting |
A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer |
|
|
Interventional
|
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD)
- Recommended Phase 2 doses (RP2Ds)
- Number of participants with treatment-emergent adverse events
- (and 6 more...)
|
51 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02747342 |
SHR3680-002 |
|
September 2016 |
June 2020 |
September 2020 |
April 21, 2016 |
February 21, 2019 |
|
- Border Medical Oncology
Albury, New South Wales, Australia - Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia - St George Hospital
Kogarah, New South Wales, Australia - (and 2 more...)
|
|
| 59 |
NCT00629057 |
Completed |
A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer |
- Androgen-insensitive Prostate Cancer
|
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To evaluate the safety and tolerability of single and multiple injection regimens of MVA-BN®-PRO for the treatment of androgen-insensitive prostate cancer.
- To evaluate the ability of MVA-BN®-PRO to generate humoral and cellular immune responses to prostate antigens, and to define an optimal dose for future studies.
|
24 |
Male |
18 Years to 75 Years (Adult, Older Adult) |
NCT00629057 |
BNIT-PR-001 |
BNIT-PR-001 |
March 2008 |
December 2010 |
September 2011 |
March 5, 2008 |
March 13, 2019 |
|
- Urology Centers of Alabama
Homewood, Alabama, United States - Walter Reed Army Medical Center
Washington, District of Columbia, United States - Lawrenceville Urology
Lawrenceville, New Jersey, United States - (and 4 more...)
|
|
| 60 |
NCT03076203 |
Recruiting |
Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad) |
- Prostate Carcinoma Metastatic to the Bone
- Stage IV Prostate Adenocarcinoma
- Hormone-refractory Prostate Cancer
|
- Drug: Niraparib
- Radiation: Radium Ra 223 Dichloride
|
Interventional
|
Phase 1 |
- Sidney Kimmel Cancer Center at Thomas Jefferson University
- Janssen, LP
- Prostate Cancer Clinical Trials Consortium
- (and 2 more...)
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose of niraparib to combine with radium Ra 223 dichloride based on dose limiting toxicities graded by National Cancer Institute, Common Toxicity Criteria, version 4.0
|
6 |
Male |
18 Years and older (Adult, Older Adult) |
NCT03076203 |
16G.085 |
|
September 22, 2017 |
November 2020 |
November 2021 |
March 10, 2017 |
March 8, 2019 |
|
- University of Alabama
Birmingham, Alabama, United States - University of Chicago Medical Center
Chicago, Illinois, United States - Tulane University
New Orleans, Louisiana, United States - (and 3 more...)
|
|
| 61 |
NCT02654938 |
Completed |
Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer |
|
- Drug: Mobilan (M-VM3)
- Drug: Placebo
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Frequency and intensity of adverse events (according to CTCAE v 4.03 classification)
- Exposure of Mobilan DNA vector in patient's peripheral blood
- Prostate-specific antigen (PSA) measure
- (and 5 more...)
|
32 |
Male |
45 Years to 75 Years (Adult, Older Adult) |
NCT02654938 |
PNC-M-VM3-01 |
|
July 2015 |
September 2017 |
September 2017 |
January 13, 2016 |
September 20, 2017 |
|
- Federal State Budgetary Institution "Russian Oncological Research Center named after N. N. Blokhin" of the Russian Academy of Sciences
Moscow, Russian Federation - Moscow Scientific Research Institute of Oncology named after P. A. Hertsen of the Ministry of Health of the Russian Federation
Moscow, Russian Federation - Moscow State Budgetary Healthcare Institution "City Clinical Hospital № 57" of Moscow Healthcare Department
Moscow, Russian Federation - (and 3 more...)
|
|
| 62 |
NCT00201357 |
Completed |
An Open Trial to Assess the Efficacy and Safety of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer |
- Hormone-refractory Prostate Cancer
|
- Drug: Thalidomide (THADO)
|
Interventional
|
Phase 2 |
- National Health Research Institutes, Taiwan
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary objective is to determine the proportion of patients who have 50% decrease in PSA maintained for at least 4 weeks, in advanced hormone-refractory prostate cancer (HRPC) patients who receive thalidomide (100 mg BID).
- Secondary objectives include the objective tumor response rate for measurable lesions, the median duration of tumor response, median time to disease progression and assessments of clinical benefits, quality of life, and safety profile.
|
30 |
Male |
18 Years and older (Adult, Older Adult) |
NCT00201357 |
T1802 |
|
October 2002 |
July 2004 |
July 2004 |
September 20, 2005 |
March 25, 2016 |
|
- Mackay Memorial Hospital
Taipei, Taiwan
|
|
| 63 |
NCT00002924 |
Completed |
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy |
|
|
Observational
|
|
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- overall survival
- response rate
|
184 |
Male |
Child, Adult, Older Adult |
NCT00002924 |
CALGB-9663
U10CA031946
CDR0000065329 |
|
January 1997 |
June 2006 |
June 2006 |
May 24, 2004 |
July 14, 2016 |
|
- Veterans Affairs Medical Center - Birmingham
Birmingham, Alabama, United States - University of California San Diego Cancer Center
La Jolla, California, United States - UCSF Cancer Center and Cancer Research Institute
San Francisco, California, United States - (and 46 more...)
|
|
| 64 |
NCT00126230 |
Terminated |
Trial of Docetaxel-Samarium in Patients With Hormone-Refractory Advanced Prostate Cancer |
|
- Drug: docetaxel and samarium
|
Interventional
|
Phase 2 |
- Gustave Roussy, Cancer Campus, Grand Paris
- Gustave Roussy, Cancer Campus, Grand Paris
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time to progression
- Prostate specific antigen (PSA) response rate
- Toxicity
- Overall survival
|
55 |
Male |
18 Years to 80 Years (Adult, Older Adult) |
NCT00126230 |
TAX-SAMAR |
|
January 2004 |
|
|
August 3, 2005 |
September 11, 2006 |
|
- Institut Gustave Roussy
Villejuif, France
|
|
| 65 |
NCT00494338 |
Terminated |
Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer |
- Metastatic Prostate Cancer
|
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Efficacy of docetaxel and celecoxib by PSA response defined as a 50% reduction in PSA maintained on two consecutive evaluations at least 4 weeks apart
- Response in measurable disease by response evaluation criteria in solid tumors (RECIST) criteria, time to progression, overall survival and toxicity by Natonal Cancer Institute Commum Toxicity Criteria version 2.0.
|
6 |
Male |
18 Years and older (Adult, Older Adult) |
NCT00494338 |
XRP6976J_2504 |
|
November 2004 |
April 2005 |
April 2005 |
June 29, 2007 |
October 1, 2009 |
|
- Sanofi-Aventis
Sao Paulo, Brazil
|
|
| 66 |
NCT00583492 |
Completed
Has Results |
Randomized Trial of Suicide Gene Therapy and Prostate Cancer |
|
- Biological: Ad5-yCD/mutTKSR39rep-ADP
- Radiation: IMRT
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Freedom From Biochemical/Clinical Failure (FFF)
- Acute >= Grade 3 Treatment-related Toxicity
- Positive Prostate Biopsy at 2 Years
- (and 3 more...)
|
44 |
Male |
18 Years and older (Adult, Older Adult) |
NCT00583492 |
Prostate4809 |
ReCAP |
December 2007 |
September 2013 |
September 2013 |
December 31, 2007 |
March 17, 2016 |
March 17, 2016 |
- Johns Hopkins University School of Medicine
Baltimore, Maryland, United States - Henry Ford Health System
Detroit, Michigan, United States
|
|
| 67 |
NCT02663908 |
Recruiting |
A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease |
|
- Drug: Degarelix
- Drug: Leuprolide
|
Interventional
|
Phase 3 |
- Ferring Pharmaceuticals
- Memorial Sloan Kettering Cancer Center
- Duke Clinical Research Institute
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time from randomization to the first confirmed (adjudicated) occurrence of the composite Major Adverse Cardiovascular Event (MACE) endpoint
- Time from randomization to occurrence of myocardial infarction (fatal, non-fatal)
- Time from randomization to occurrence of stroke (fatal, non-fatal)
- (and 3 more...)
|
900 |
Male |
Child, Adult, Older Adult |
NCT02663908 |
000108 |
PRONOUNCE |
April 2016 |
July 2021 |
July 2021 |
January 26, 2016 |
March 28, 2019 |
|
- Urology Center of Alabama PC
Birmingham, Alabama, United States - Alaska Clinical Research Center
Anchorage, Alaska, United States - Arizona Institute of Urology
Tucson, Arizona, United States - (and 122 more...)
|
|
| 68 |
NCT00035997 |
Completed |
Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis |
|
|
Interventional
|
Phase 4 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Changes in bone mineral density of the lumbar spine (L2-L4) at 12 months
- Changes in biochemical markers of bone turnover over 12 months
- Changes in bone mineral density of the total hip at 12 months
- (and 2 more...)
|
261 |
Male |
18 Years and older (Adult, Older Adult) |
NCT00035997 |
CZOL446EUS24
US24 |
|
April 2002 |
January 2004 |
January 2004 |
May 8, 2002 |
November 23, 2009 |
|
- Norwood Clinic
Birmingham, Alabama, United States - Alaska Clinical Research Center, LLC
Anchorage, Alaska, United States - Advanced Urology Medical Center
Anaheim, California, United States - (and 53 more...)
|
|
| 69 |
NCT03294889 |
Recruiting |
ONE-SHOT Trial - Ultra-hypofractionated Single-dose SBRT for Prostate Cancer |
|
- Radiation: Stereotactic body radition (SBRT)
|
Interventional
|
Phase 1
Phase 2 |
- University Hospital, Geneva
- Humanitas Hospital, Italy
- University of Zurich
- Kantonsspital Graubünden
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical performance
- Progression free survival (PFS)
|
45 |
Male |
18 Years to 85 Years (Adult, Older Adult) |
NCT03294889 |
2017-01236 |
|
September 1, 2017 |
October 1, 2020 |
October 1, 2030 |
September 27, 2017 |
August 1, 2018 |
|
- University Hospital of Geneva
Genève, Switzerland
|
|
| 70 |
NCT00955435 |
Active, not recruiting |
Study of Blood and Urine Samples in Patients With Newly Diagnosed Localized Prostate Cancer Treated With Hormone Therapy and Radiation Therapy. ICORG 06-15 |
|
- Drug: bicalutamide
- Drug: releasing hormone agonist therapy
- Genetic: protein expression analysis
- (and 3 more...)
|
Observational
|
|
- Cancer Trials Ireland
- Cancer Trials Ireland
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Changes in serum and urine proteomic profiles
- Prognostic and biochemical markers of early disease progression
- Protein expression and temporal alterations
- Molecular targets
|
60 |
Male |
18 Years and older (Adult, Older Adult) |
NCT00955435 |
CTRIAL-IE (ICORG) 06-15
EU-20921 |
|
September 2005 |
October 2012 |
|
August 10, 2009 |
July 24, 2018 |
|
- Beacon Hospital
Dublin, Ireland - Saint Luke's Radiation Oncology Network
Dublin, Ireland
|
|
| 71 |
NCT02391051 |
Recruiting |
Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial |
|
- Radiation: HDR-Brachytherapy
|
Interventional
|
Phase 2 |
- University of Erlangen-Nürnberg Medical School
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Intensity and frequency of adverse events
- Tumor regression
- Rate of recurrences measured by PSA
- (and 3 more...)
|
50 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02391051 |
FOKAL-BT |
FOKAL-BT |
October 2014 |
December 2019 |
December 2029 |
March 18, 2015 |
August 11, 2017 |
|
- University Hospital
Erlangen, Germany
|
|
| 72 |
NCT02257827 |
Completed |
Trial Comparing Intensity Modulated Radiotherapy Versus Conformal Radiotherapy to Treat Prostate Cancer With Hypofractionated Schedule |
|
|
Interventional
|
Phase 3 |
- Gustavo Viani Arruda
- Marilia Medicine School
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Gastrointestinal and geniturinary acute toxicity
- Gastrointestinal and geniturinary late toxicity
- Biochemical control
|
220 |
Male |
18 Years to 75 Years (Adult, Older Adult) |
NCT02257827 |
FAMEMA-0913 |
|
January 2009 |
January 2013 |
January 2013 |
October 6, 2014 |
October 6, 2014 |
|
- Faculty of Medicine of Marilia
Marilia, Sao Paulo, Brazil
|
|
| 73 |
NCT00006371 |
Terminated |
A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer |
|
- Drug: aminoglutethimide
- Drug: ketoconazole
- Drug: therapeutic hydrocortisone
|
Interventional
|
Phase 2 |
- H. Lee Moffitt Cancer Center and Research Institute
- National Cancer Institute (NCI)
- Janssen Pharmaceuticals
- H. Lee Moffitt Cancer Center and Research Institute
|
Other / NIH / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate (ORR) for Treatment Arm
|
2 |
Male |
Child, Adult, Older Adult |
NCT00006371 |
MCC-12219
NCI-G00-1863 |
|
May 2000 |
December 2001 |
December 2001 |
April 2, 2004 |
September 27, 2012 |
|
- H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
|
|
| 74 |
NCT00805701 |
Completed |
Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation |
|
- Drug: avodart
- Drug: Placebo
|
Interventional
|
Phase 4 |
- Bay State Clinical Trials, Inc.
- GlaxoSmithKline
- Bay State Clinical Trials, Inc.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- the effect of dutasteride on dysuria, voiding and LUTS
|
40 |
Male |
35 Years to 90 Years (Adult, Older Adult) |
NCT00805701 |
047838 |
|
January 2009 |
April 2014 |
April 2014 |
December 10, 2008 |
May 14, 2014 |
|
- Bay State Clinical Trials, Inc.
Watertown, Massachusetts, United States
|
|
| 75 |
NCT03639649 |
Completed |
STHLM3 - Prostate Cancer Diagnostic Trial |
|
|
Interventional
|
Not Applicable |
- Karolinska Institutet
- Stockholm County Council, Sweden
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Diagnostic
|
- Number of biopsies
- Number of Gleason Score ≥ 7
- Number of Gleason Score 6
- Number of benign
|
58818 |
Male |
50 Years to 69 Years (Adult, Older Adult) |
NCT03639649 |
Karolinska1 |
STHLM3 |
August 2013 |
February 2015 |
February 2015 |
August 21, 2018 |
August 21, 2018 |
|
- Karolinska Institutet
Stockholm, Sweden
|
|
| 76 |
NCT02058706 |
Active, not recruiting |
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer |
- Adenocarcinoma of the Prostate
- Recurrent Prostate Cancer
- Stage IV Prostate Cancer
|
- Drug: enzalutamide
- Drug: bicalutamide
- Procedure: orchiectomy
- (and 3 more...)
|
Interventional
|
Phase 2 |
- Barbara Ann Karmanos Cancer Institute
- National Cancer Institute (NCI)
- Barbara Ann Karmanos Cancer Institute
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Achievement of PSA remission assessed using the Prostate Cancer Clinical Trials Working Group (PCWG2) criteria
- Achievement of measurable disease assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- Achievement of PSA response assessed using PCWG2 criteria
- (and 11 more...)
|
92 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02058706 |
2013-083
NCI-2014-00212
1311012529
P30CA022453 |
|
May 2014 |
December 31, 2018 |
December 31, 2018 |
February 10, 2014 |
February 13, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States - Henry Ford Hospital
Detroit, Michigan, United States - Ohio State University Medical Center
Columbus, Ohio, United States
|
|
| 77 |
NCT00003645 |
Completed |
Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence |
|
- Drug: Flutamide
- Drug: Leuprolide Acetate
|
Interventional
|
Phase 3 |
- M.D. Anderson Cancer Center
- National Cancer Institute (NCI)
- Eastern Cooperative Oncology Group
- (and 2 more...)
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Patients with Disease-free Survival at 5 Years
|
64 |
Male |
Child, Adult, Older Adult |
NCT00003645 |
ID97-077
P30CA016672
MDA-ID-97077
E-97077
NCI-T97-0069
CDR0000066733
NCI-2009-00818 |
|
June 14, 1999 |
March 20, 2017 |
March 20, 2017 |
July 15, 2003 |
March 23, 2017 |
|
- University of Texas - MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 78 |
NCT00554229 |
Completed
Has Results |
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases |
|
- Drug: ZD4054
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Overall Survival
- Progression Free Survival
- Time to Use of Opiates
- (and 7 more...)
|
896 |
Male |
18 Years and older (Adult, Older Adult) |
NCT00554229 |
D4320C00014
2007-003227-20 |
ENTHUSE M1 |
November 2007 |
July 2010 |
August 2011 |
November 6, 2007 |
February 8, 2016 |
May 31, 2012 |
- Research Site
Tucson, Arizona, United States - Research Site
Greenbrae, California, United States - Research Site
Los Angeles, California, United States - (and 196 more...)
|
|
| 79 |
NCT02726009 |
Recruiting |
A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer |
|
|
Interventional
|
Phase 4 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Frequency of adverse events
- Severity of adverse events
- Clinically significant changes in laboratory values (hematology and clinical biochemistry)
- (and 5 more...)
|
230 |
Male |
18 Years to 79 Years (Adult, Older Adult) |
NCT02726009 |
000201 |
|
May 2016 |
March 2020 |
March 2020 |
April 1, 2016 |
October 12, 2018 |
|
- S. P Medical College and AG of Hospitals
Bikaner, Rajasthan, India - Krishna Institute of Medical Sciences
Secunderabad, Telangana, India - Bodyline Hospitals
Ahmedabad, India - (and 21 more...)
|
|
| 80 |
NCT01238172 |
Completed
Has Results |
Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance |
|
- Other: dietary education and counseling
- Other: prostate cancer foundation booklet
|
Interventional
|
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time to Progression
- Time to Treatment: Censoring Death, Progression or Last Follow-up as Measured by Number of Events Observed
- Quality of Life (QOL) Was Measured Using Change From Baseline in Total Summary Score of Memorial Anxiety Scale for Prostate Cancer (MAX-PC) at Month 24
- Total Vegetables (Servings Per Day) Evaluated at Baseline and Month 24 Based on Dietary Recall
|
478 |
Male |
50 Years to 80 Years (Adult, Older Adult) |
NCT01238172 |
CALGB-70807
CDR0000687958 |
|
January 2011 |
November 18, 2017 |
January 15, 2019 |
November 10, 2010 |
March 12, 2019 |
March 12, 2019 |
- Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
Fairbanks, Alaska, United States - Mayo Clinic Scottsdale
Scottsdale, Arizona, United States - Kaiser Permanente Medical Center - Bellflower
Bellflower, California, United States - (and 177 more...)
|
|
| 81 |
NCT03819101 |
Not yet recruiting |
Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer |
|
- Drug: Acetylsalicylic acid
- Drug: Atorvastatin
|
Interventional
|
Phase 3 |
- Gustave Roussy, Cancer Campus, Grand Paris
- National Cancer Institute, France
- Gustave Roussy, Cancer Campus, Grand Paris
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
1210 |
Male |
18 Years and older (Adult, Older Adult) |
NCT03819101 |
2017-004639-35
2017/2601 |
PEACE-4 |
March 2019 |
March 2034 |
March 2038 |
January 28, 2019 |
January 28, 2019 |
|
- Gustave Roussy Cancer Campus Grand Paris
Villejuif, Val De Marne, France
|
|
| 82 |
NCT03663218 |
Recruiting |
PreOperative RadioTherapy for High-Risk Prostate Cancer (PORT-PC Trial) |
|
- Radiation: Dose escalation
|
Interventional
|
Not Applicable |
- Weill Medical College of Cornell University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Assessing if patients can undergo a radical prostatectomy after SBRT without a post-operative gastrointestinal or urinary grade 4 or 5 toxicity (NCI Common terminology criteria for adverse events) within 30 days related to preoperative radiotherapy.
- Acute toxicity in patients after stereotactic body radiotherapy (SBRT) and radical prostatectomy (RP) will be assessed based on NCI Common terminology criteria for adverse events (CTCAE) version 5.0.
- Quality of life scores in patients after stereotactic body radiotherapy (SBRT) and radical prostatectomy (RP) will be collected.
|
40 |
Male |
18 Years to 90 Years (Adult, Older Adult) |
NCT03663218 |
1712018849 |
PORT-PC |
October 24, 2018 |
December 30, 2020 |
December 31, 2022 |
September 10, 2018 |
October 26, 2018 |
|
- Weill Cornell Medicine
New York, New York, United States
|
|
| 83 |
NCT00215345 |
Unknown † |
A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer |
|
- Drug: Taxotere
- Drug: Celecoxib
|
Interventional
|
Phase 2 |
- Department of Veterans Affairs, New Jersey
- Pfizer
- Sanofi
|
U.S. Fed / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine the effect of Taxotere and celecoxib on PSA and objective response in patients with HRPC
- Evaluate the toxicity of the combination of celecoxib and Taxotere in patients with stage D3 prostate cancer.
- Determine the effects of this regimen on quality of life.
- Determine the survival of the patients treated
|
66 |
Male |
18 Years and older (Adult, Older Adult) |
NCT00215345 |
COXAON-0509-047
GIA16125 |
|
August 2002 |
|
December 2006 |
September 22, 2005 |
September 22, 2005 |
|
- Department Of Veterans Affairs NJ Health Care System
East Orange, New Jersey, United States
|
|
| 84 |
NCT03077659 |
Completed |
Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer |
- Adenocarcinoma of the Prostate
|
|
Interventional
|
Phase 2 |
- NanOlogy, LLC
- US Biotest, Inc.
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of Treatment Emergent Adverse Events (safety and tolerability)
- Pharmacokinetics: Area under the plasma concentration versus time curve (AUC) of NanoPac®
- Pharmacokinetics: Peak plasma concentration (Cmax) of NanoPac®
- (and 4 more...)
|
30 |
Male |
18 Years and older (Adult, Older Adult) |
NCT03077659 |
NANOPAC-2016-02 |
|
September 6, 2017 |
October 4, 2018 |
October 4, 2018 |
March 13, 2017 |
November 27, 2018 |
|
- University of Southern California
Los Angeles, California, United States
|
|
| 85 |
NCT02278055 |
Active, not recruiting |
Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer |
- Metastatic Prostate Cancer
- Pain
|
|
Interventional
|
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- University of North Carolina
- New York-Presbyterian Hospital Cornell Medical Center
- Memorial Sloan Kettering Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- pain response
- Changes in Bone Alkaline phosphatase (ALP)
- Changes in other bone markers:
|
29 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02278055 |
14-098
c13-124 |
|
October 8, 2014 |
October 2019 |
October 2019 |
October 29, 2014 |
August 6, 2018 |
|
- Memorial Sloan Kettering Cancer Center
New York, New York, United States - New York Presbyterian Hospital-Weill Medical College of Cornell University
New York, New York, United States - University of North Carolina
Chapel Hill, North Carolina, United States
|
|
| 86 |
NCT02768363 |
Recruiting |
Randomized Controlled Trial of ProstAtak® Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) |
|
- Biological: aglatimagene besadenovec
- Biological: placebo
- Drug: valacyclovir
|
Interventional
|
Phase 2
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Proactive surveillance score
- Biochemical response (change in PSA)
- Patient reported Health Related Quality of Life
- (and 2 more...)
|
156 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02768363 |
PrTK04 |
|
May 2016 |
December 2019 |
|
May 11, 2016 |
April 3, 2019 |
|
- Foothills Urology
Golden, Colorado, United States - 21st Century Oncology
Fort Lauderdale, Florida, United States - Jesse Brown VA Medical Center
Chicago, Illinois, United States - (and 24 more...)
|
|
| 87 |
NCT02514213 |
Completed |
Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer |
|
- Biological: 2mg INO-5150 and electroporation device CELLECTRA®-5P
- Biological: 8.5mg INO-5150 and electroporation device CELLECTRA®-5P
- Biological: 2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P
- (and 2 more...)
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety and tolerability of INO-5150 alone or with INO-9012 delivered via IM EP ( Incidence of adverse events, Injection site reactions, Changes in safety laboratory parameters)
- Antigen specific immune response of INO-5150 alone or with INO-9012 delivered via IM EP
- PSA response rate by PSA testing
|
62 |
Male |
18 Years to 90 Years (Adult, Older Adult) |
NCT02514213 |
PCa-001 |
|
July 2015 |
December 12, 2017 |
December 12, 2017 |
August 3, 2015 |
December 26, 2017 |
|
- Chesapeake Urology Research Associates
Baltimore, Maryland, United States - Karmanos Cancer Institute
Detroit, Michigan, United States - GU Research Network, LLC/ Urology Cancer Center
Omaha, Nebraska, United States - (and 7 more...)
|
|
| 88 |
NCT03514836 |
Recruiting |
A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer |
- Castration-resistant Prostate Cancer
|
- Biological: DCVac/PCa
- Drug: Cyclophosphamide
|
Interventional
|
Phase 1
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival
- Overall Survival
- Safety
- (and 2 more...)
|
15 |
Male |
18 Years and older (Adult, Older Adult) |
NCT03514836 |
SP015 |
|
May 23, 2018 |
April 2020 |
April 2021 |
May 2, 2018 |
June 12, 2018 |
|
- Fakultní nemocnice v Motole
Praha, Czechia
|
|
| 89 |
NCT00946920 |
Completed
Has Results |
A Trial of Degarelix in Patients With Prostate Cancer |
|
- Drug: Degarelix
- Drug: Goserelin acetate
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Cumulative Probability of Testosterone at Castrate Level (≤0.5 ng/mL) With Degarelix
- Difference in Cumulative Probability of Testosterone at Castrate Level (≤0.5 ng/mL) Between Degarelix and Goserelin
- Serum Levels of Testosterone Over Time
- (and 3 more...)
|
859 |
Male |
18 Years and older (Adult, Older Adult) |
NCT00946920 |
FE200486 CS35
2008-005276-27 |
|
June 2009 |
March 2011 |
March 2011 |
July 27, 2009 |
June 2, 2014 |
June 2, 2014 |
- Urology Centers Of Alabama
Homewood, Alabama, United States - Arkansas Urology
Little Rock, Arkansas, United States - Urology Associates of Central CA
Fresno, California, United States - (and 123 more...)
|
|
| 90 |
NCT02302105 |
Active, not recruiting |
Randomized Trial of Prostate Only or Pelvic RT in High Risk Prostate Cancer |
|
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Biochemical Disease Free Survival
|
224 |
Male |
Child, Adult, Older Adult |
NCT02302105 |
POP-RT |
POP-RT |
November 2011 |
January 2021 |
|
November 26, 2014 |
July 9, 2018 |
|
- Dr Vedang Murthy
Navi-Mumbai, Maharashtra, India
|
|
| 91 |
NCT00480623 |
Terminated |
A Phase I Trial of Satraplatin Plus Radiation Therapy for Prostate Cancer Patients With Biochemical Recurrence |
|
- Drug: Satraplatin plus radiation therapy
|
Interventional
|
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine maximum tolerated dose and dose limiting toxicity for the combination of Satraplatin and radiation therapy.
- PSA Response, Time to PSA Response, Duration of PSA response, Secondary Biochemical Recurrence Free Survival, Time to Biochemical Recurrence, Effect of Satraplatin on Serum Testosterone Levels, Safety and Tolerability.
|
|
Male |
18 Years and older (Adult, Older Adult) |
NCT00480623 |
SAT1-06-01 |
|
May 2007 |
March 2008 |
April 2008 |
May 31, 2007 |
March 23, 2012 |
|
- University of California San Francisco
San Francisco, California, United States - UT Southwestern Medical Center at Dallas
Dallas, Texas, United States - The University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States - Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 92 |
NCT02293707 |
Active, not recruiting |
A Phase II Randomised Trial of Three Regimens of GX301 Vaccination in Castration-resistant Prostate Cancer |
|
|
Interventional
|
Phase 2 |
- Laboratoires Leurquin Mediolanum
- Universita degli Studi di Genova
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Achievement of immunological response
- Incidence of adverse events
- Changes from baseline in laboratory tests for immunological safety
- (and 3 more...)
|
120 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02293707 |
MED-GX301-02
2014-000095-26 |
|
November 2014 |
August 2018 |
December 2019 |
November 18, 2014 |
September 5, 2018 |
|
- S.C. di Oncologia, A.S.O. "Santi Antonio e Biagio e Cesare Arrigo"
Alessandria, Italy - Oncologia Medica A, Centro di Riferimento Oncologico (CRO)
Aviano, Italy - Oncologia Medica, Azienda Ospedaliero Universitaria - Policlinico Consorziale
Bari, Italy - (and 21 more...)
|
|
| 93 |
NCT01260688 |
Completed
Has Results |
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel |
- Hormone Refractory Prostate Cancer
- Recurrent Prostate Cancer
|
- Drug: cediranib maleate
- Drug: dasatinib
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 12-week Progression-free Survival as Per the Prostate Cancer Clinical Trials Working Group (PCWG2)
- Number of Participants With Toxicities
- Qualtiy of Life Assessment Number of Participants With a Score ≥2 on the Present Pain Intensity (PPI) Scale
- (and 11 more...)
|
22 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01260688 |
NCI-2011-02544
PMH-PJC-002
PJC-002
8476
U01CA070095
U01CA132123
N01CM00071 |
|
October 2010 |
January 2013 |
February 2014 |
December 15, 2010 |
August 8, 2018 |
December 5, 2013 |
- Illinois CancerCare-Peoria
Peoria, Illinois, United States - Central Illinois Hematology Oncology Center
Springfield, Illinois, United States - Fort Wayne Medical Oncology and Hematology Inc - State Boulevard
Fort Wayne, Indiana, United States - (and 5 more...)
|
|
| 94 |
NCT02526784 |
Completed |
A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer |
|
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Difference in the average patient reported injection site pain score between patients receiving the optimised and standard s.c. injections, as well as between patients receiving the i.m. and standard s.c. injections
- Patient reported injection site pain scores after degarelix starting dose
- Patient reported injection site pain scores after degarelix maintenance doses
- Difference in skin colour values between pre- and post-injection
|
120 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02526784 |
000184
2015-000357-20 |
|
December 2015 |
May 2017 |
June 2017 |
August 18, 2015 |
July 5, 2017 |
|
- Tampereen yliopistollinen sairaala (there may be other sites in this country)
Tampere, Finland - Groupe Hospitalier Pellegrin Tripode (there may be other sites in this country)
Bordeaux, France - Universitaetsklinikum Freiburg (there may be other sites in this country)
Freiburg, Germany
|
|
| 95 |
NCT01682772 |
Recruiting |
TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate Cancer |
- Adenocarcinoma of the Prostate
|
|
Interventional
|
Phase 2 |
- Institute of Cancer Research, United Kingdom
- Royal Marsden NHS Foundation Trust
- Institute of Cancer Research, United Kingdom
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate to Olaparib
- Radiographic progression free survival
- Progression free survival
- (and 7 more...)
|
89 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01682772 |
ICR-CTSU/2011/10030
2011-000601-49
CRUK/C12540/A12354
ISRCTN15124653
ISS22810018 |
TOPARP |
July 2012 |
February 2019 |
December 2019 |
September 11, 2012 |
August 10, 2018 |
|
- Royal Marsden NHS Foundation Trust
Sutton, Surrey, United Kingdom - University College Hospital London
London, United Kingdom
|
|
| 96 |
NCT03241537 |
Recruiting |
COHORT Trial in Clinical Pelivc Lymph Node Metastatic Prostate Cancer |
|
- Radiation: Intensity modulated radiotherapy
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Comparison of overall survival between two treatment groups
- Comparison of toxicities between two treatment groups
- Comparison of quality of lifl between two treatment groups
- (and 3 more...)
|
246 |
Male |
20 Years and older (Adult, Older Adult) |
NCT03241537 |
SMC2015-11-139-002 |
|
January 15, 2016 |
January 14, 2019 |
January 14, 2026 |
August 7, 2017 |
April 16, 2019 |
|
- Samsung Medical Center
Seoul, Korea, Republic of
|
|
| 97 |
NCT03091764 |
Recruiting |
Evaluation of a Patient-Reported Symptom Index for NMIBC |
- Superficial Bladder Cancer
|
|
Observational
|
|
- University of Sydney
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- Cancer Australia
- Cancer Council New South Wales
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
450 |
All |
18 Years and older (Adult, Older Adult) |
NCT03091764 |
APP1103036 |
|
July 1, 2016 |
June 30, 2019 |
June 30, 2020 |
March 27, 2017 |
March 28, 2019 |
|
- University of Kansas
Kansas City, Kansas, United States - University of Minnesota
Minneapolis, Minnesota, United States - Mayo Clinic
Rochester, Minnesota, United States - (and 13 more...)
|
|
| 98 |
NCT00208988 |
Completed |
A Randomized Controlled Trial to Promote Physician-Patient Discussion of Prostate Cancer Screening |
|
- Procedure: Educational handout about prostate cancer screening
- Procedure: Simple cue for patient to talk to doctor
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Single
- Primary Purpose: Educational/Counseling/Training
|
- Discussion of Prostate Cancer Screening
- DRE
- PSA
|
250 |
Male |
45 Years to 70 Years (Adult, Older Adult) |
NCT00208988 |
511-2005 |
|
May 2003 |
|
August 2003 |
September 21, 2005 |
September 21, 2005 |
|
- Grady Memorial Hospital
Atlanta, Georgia, United States
|
|
| 99 |
NCT00684970 |
Unknown † |
Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC) |
- Metastatic Castration Resistant Prostate Cancer (CRPC)
|
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival (PFS) measured 24 weeks after treatment initiation
- Overall Survival, Time to PSA Progression, PSA Response, Pain Response measured in evaluable patients.
- Safety and tolerability
|
100 |
Male |
18 Years and older (Adult, Older Adult) |
NCT00684970 |
TLH-202 |
TLH-202 |
March 2009 |
February 2014 |
|
May 28, 2008 |
December 5, 2013 |
|
- Bnei Tzion Medical Center
Haifa, Israel - Rambam Medical Center
Haifa, Israel - Sheba Medical Center
Tel Hashomer, Israel - (and 2 more...)
|
|
| 100 |
NCT00003653 |
Completed |
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer |
|
- Drug: bicalutamide
- Drug: buserelin
- Drug: cyproterone acetate
- (and 4 more...)
|
Interventional
|
Phase 3 |
- NCIC Clinical Trials Group
- National Cancer Institute (NCI)
- Southwest Oncology Group
- Canadian Cancer Trials Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Time to hormone resistance
- Quality of life by European Organization for Research of the Treatment of Cancer Quality of Life Questionnaire-C30+ (EORTC QLQ-C30+) trial specific checklist
- (and 4 more...)
|
1386 |
Male |
16 Years to 120 Years (Child, Adult, Older Adult) |
NCT00003653 |
PR7
CAN-NCIC-PR7
SWOG-JPR7
ICR-CTSU-JPR7
CDR0000066745 |
|
January 1999 |
May 2010 |
January 2013 |
January 27, 2003 |
November 28, 2016 |
|
- Tom Baker Cancer Centre
Calgary, Alberta, Canada - Cross Cancer Institute
Edmonton, Alberta, Canada - BCCA - Cancer Centre for the Southern Interior
Kelowna, British Columbia, Canada - (and 26 more...)
|
|
Create an RSS feed from your search for:
Download the search results for: